List view / Grid view
16 September 2024 | By Drug Target Review
The increasing use of AI in the life science field marks a pivotal point in history. Although AI is now an indispensable tool in drug discovery, promising to save vast amounts of time and money, there are still many hurdles scientists encounter. This webinar will explore these challenges and offer…
In this article, Dr Robert Scoffin, Chairman and CEO at Cresset, explores FEP and its current challenges, and outlines how continuous advancements and strategic approaches are helping to drive the adoption of FEP methods in drug discovery.
The potential for brain organoids to develop consciousness is a key issue in neuroscience, which has prompted new ethical considerations.
22 January 2024 | By Drug Target Review, sponsored by Bio Rad Technologies
Watch this webinar to learn how the challenges with using certain viral vectors in gene therapy has advanced the development of a new generation of precise vectors with sustainable effects. Our experts outline the limitations of existing vectors and how these can be overcome using modified recombinant non-replicative herpes simplex…
21 December 2023 | By
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.
A new Drug Target Review issue is now ready to download! This issue features articles on vaccine development, artificial intelligence and organoids.
Bare minimum reimbursement rates could be why some clinics may be struggling to offer HPV vaccination in the US.
Guidelines unveiled at AAIC 2023 using blood biomarkers offer faster and more effective Alzheimer's diagnosis.
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
A fast, easy, and streamlined method for characterizing cytokine identity and purity with automated capillary electrophoresis (icIEF and CE-SDS).
Japanese researchers debate if human brain organoids that are cultivated from stem cells and serve as a model of human brain development, can be legally considered a person.
Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure.
A new Drug Target Review is now ready to download! This issue features articles which explore antibodies, vaccines and assays.
Explore current insights into the clinical possibilities posed by organoids and delve into short and long-term prospects for therapeutic screening and personalised regenerative medicine in this whitepaper.
Join Malvern Panalytical for a 15-minute webinar to learn about ex vivo inflammasome slice assays for neuroinflammation discovery.
